EUCTR2008-003368-21-IT进行中（未招募）不适用
Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) - Trial of Abatacept in IPEX syndrome
ISTITUTO PER L`INFANZIA BURLO GAROFOLO0 个研究点开始时间: 2009年2月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Confirmed diagnosis of IPEX. Unfavourable cost/benefit ratio for Hematopoietic Stem Cell Transplantation. In particular: 1)patients who already developed autoimmune disorders and/or organ failure because of the disease 2)disease not fully controlled by an intensive treatment at doses of conventional immunosuppressants producing severe side effects (infections, adrenal-hypotalamic suppression).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Positivity for mycobacterius tuberculosis infection.
研究者
相似试验
已完成
2 期
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1Abnormal Glucose ToleranceType 1 DiabetesNCT01773707National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)212
进行中（未招募）
1 期
Preventing Abnormal Glucose Tolerance and Diabetes with an Antibody in Relatives at Risk for the DiseaseA soluble fusion protein, CTLA-4 Ig, is to be used for the prevention ofabnormal glucose tolerance and diabetes in relatives at risk ofdeveloping the disease.MedDRA version: 20.1Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-002249-13-FITrialNet Coordinating Center206
进行中（未招募）
不适用
Preventing Abnormal Glucose Tolerance and Diabetes with an Antibody in Relatives at Risk for the DiseaseA soluble fusion protein, CTLA-4 Ig, is to be used for the prevention ofabnormal glucose tolerance and diabetes in relatives at risk ofdeveloping the disease.MedDRA version: 17.0Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-002249-13-ITTrialNet Coordinating Center206
进行中（未招募）
1 期
Preventing Abnormal Glucose Tolerance and Diabetes with an Antibody in Relatives at Risk for the DiseaseEUCTR2013-002249-13-SETrialNet Coordinating Center206
进行中（未招募）
1 期
Preventing Abnormal Glucose Tolerance and Diabetes with an Antibody in Relatives at Risk for the DiseaseA soluble fusion protein, CTLA-4 Ig, is to be used for the prevention ofabnormal glucose tolerance and diabetes in relatives at risk ofdeveloping the disease.MedDRA version: 21.1Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-002249-13-DETrialNet Coordinating Center206